Alembic Pharma glaucoma drug Travoprost Ophthalmic Solution gets USFDA approval

The USFDA approved Travoprost Ophthalmic Solution is a generic equivalent to Alcon Pharmaceuticals' Travatan Ophthalmic Solution, Alembic Pharmaceuticals said in a regulatory filing.

New Delhi: Drug firm Alembic Pharmaceuticals on Tuesday said it has received final approval from the US health regulator to market Travoprost Ophthalmic Solution, used in the treatment of glaucoma.

The company has received nod from US Food & Drug Administration (USFDA) for its product, which is a generic equivalent to Alcon Pharmaceuticals' Travatan Ophthalmic Solution, Alembic Pharmaceuticals said in a regulatory filing.

Alembic said its product is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Read Also: Alembic Pharma JV Aleor gets tentative USFDA nod for a therapeutic equivalent of Pennsaid Topical Solution

The company said it now has a cumulative total of 110 abbreviated new drug application (ANDA) approvals from the USFDA.

Headquartered in Vadodara, the company is involved in manufacturing pharmaceutical products, pharmaceutical substances and intermediates.

Read Also: Alembic Pharma gets USFDA nod for a generic version of Rapaflo Capsules